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ABSTRACT 
Diabetic peripheral neuropathy (DPN) is common, and is a leading cause of lower limb 
amputation and disabling neuropathic pain. Amputations have a devastating impact not only 
on the quality of life but also result in an alarmingly low life-expectancy which on average is 
only two years from the event. It also places a substantial financial burden on healthcare 
systems and society in general. Whie the prevalence of blindness in working age adults in 
the UK is falling, diabetes-related amputations are rising not only in the UK but also globally. 
This article reviews new innovations that enable the early diagnosis of DPN and assesses 
the evidence for early multiple risk factor management strategies to improve DPN. Through 
this review we put forward the case for early multifactorial interventions as the best prospect 
for preventing/halting DPN, and LW¶V devastating sequelae. 
KEYWORDS 
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INTRODUCTION 
Diabetic peripheral neuropathy (DPN) is the most common complication of both type 1 and 2 
diabetes and occurs in over half of affected individuals [1,2]. In the UK, diabetes remains the 
commonest non-traumatic cause of lower limb amputations [3]. Each week in England there 
are around 140 amputations in people with diabetes [4]. Amputation is not only devastating 
in its impact on the individual and their family, but also a leading cause for  loss of 
independence and livelihood. In low-income countries the financial costs can be equivalent 
to 5.7 years of annual income, potentially resulting in financial ruin for these patients and 
their families [5]. It also places a substantial financial burden on healthcare systems and 
society in general. In the USA, the total annual cost of managing symptomatic DPN (painful) 
and its complications (foot ulcerations and lower limb amputations) was estimated to be 
between $4.6 and $13.7 billion, with up to 27% of the direct medical costs of diabetes 
attributed to DPN [6]. Urgent action is needed in order to address this growing global health 
problem. Unfortunately, only 50 per cent of people with diabetes who have an amputation 
survives for two years [7,8]. Moreover, the relative likelihood of death within five years 
following a diabetic foot ulcer is greater than for colon, prostate and breast cancer (Figure 1) 
[9,10]. The most shocking fact of all, however, is that most of these amputations are 
preventable. It is estimated that 80% of amputations could be prevented through good 
podiatry care which not only reduces amputation risk, but also dramatically impacts the rate 
of hospitalization, and indeed re-ulceration [11].  
NATURAL HISTORY OF DIABETIC PERIPHERAL NEUROPATHY 
Diabetic peripheral neuropathy is the key initiating factor inthe development of diabetic foot 
ulceration [11]. It is a predominantly sensory neuropathy with autonomic nervous system 
involvement although there are often motor features with advancing disease. DPN is not 
only the commonest cause of non-traumatic lower limb amputations, but is also a cause of 
impaired balance and gait [12,13] and distressing neuropathic pain that is often 
unresponsive to therapy [14]. The neuropathy is symmetrical and length-dependent, 
affecting the longest nerves, hence involves the feet first [15]. Unfortunately, the early 
manifestations of this insidious disease are often missed until the disease is well 
established, at which point it appears irreversible [15].  
THE CURRENT STATE OF AFFAIRS 
1HUYHFRQGXFWLRQVWXGLHVDUHWKHFXUUHQWµJROG¶VWDQGDUGIRUWKHGLDJQRVLVRI'31>16]. This 
robust measure also predicts foot ulceration and mortality [17].  However, they are labour 
intensive, timeconsuming,costly and impractical to implement in routine clinical care. 
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Currently, there are no simple markers for early detection in routine clinical practice for DPN. 
The measures we use are crude and detect the disease very late in its natural history. Even 
the benefits gained by standardising clinical assessment using scored clinical assessments 
such as the Michigan Neuropathy Screening Instrument (MNSI) [18], the Toronto Clinical 
Neuropathy Score (TCNS) [19] and the United Kingdom Screening Test (UKST) [20], remain 
subjective, heavily reliant on the H[DPLQHUV¶ LQWHUSUHWDWLRQV [21]. Bedside tests used to aid 
diagnosis of neuropathy such as the 10g monofilament [22,23], the Ipswich Touch Test [24] 
and vibration perception threshold using the tuning fork [25] are QRWRQO\UHOLDQWRQSDWLHQWV¶
subjective response but are mainly utilised to identify the loss of protective foot sensation 
and risk of ulceration [26]. As such, these tests tend to diagnose DPN when it is already well 
established [27]. Late diagnosis hampers the benefits of intensive management at an early 
stage of disease trajectorywhich includes a focus on  intensified multifactorial intervention , 
and the prevention of neuropathy-related sequelae [28]. Conversely, the situation is different 
for the detection of diabetic retinopathy using digital camera-based retinal photography or 
diabetic kidney disease using blood and urine tests. These developments led to the 
institution of a robust annual screening program in many countries that has led to significant 
reduction in blindness [29], such that retinopathy is no longer the commonest cause of 
blindness in working age adults [30,31] and reductions in end-stage renal failure [32]. 
Unfortunately, by the time neuropathy is detected using these crude tests, it is often very 
well established and consequently impossible to reverse or even to halt the inexorable 
neuropathic process. 
RECENT DEVELOPMENTS IN STATE-OF-THE ART POINT-OF-CARE DEVICES (POCD) 
Significant progress has been made to develop point-of-care devices (POCD) that are 
capable of diagnosing early, subclinical neuropathy. Papanas et al. have recently 
comprehensively reviewed these devices [33]. Therefore, we will briefly outline the following 
devices: the NeuroQuick [34], NeuroPAD [35], NC-Stat DPN-Check [36-38], Corneal 
Confocal Microscopy (CCM) [39,40] and Sudoscan [41,42].  
1. DPN Check 
The DPN-Check is a novel, user-friendly, handheld POCD that performs a sural nerve 
conduction study in three minutes. It is an acceptable proxy for standard nerve conduction 
studies which are time-consuming, expensive and often require patients to be seen in 
specialists¶ clinics. The DPN check has been demonstrated to have excellent reliability with 
an inter- and intra-observer intraclass correlation coefficients of between 0.83 and 0.97 for 
sensory nerve action potentials respectively [36]. It also has good validity with 95% 
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sensitivity and 71% specificity when compared against reference standard nerve conduction 
study [37] [36] for the diagnosis of DPN.   
Nerve conduction studies, however, is only an assessment of large nerve fibre function. 
DPN, on the other hand, usually involves both small and large nerve fibres, with some 
evidence suggesting small nerve fibre involvement early in its natural history [43,44]. Small 
nerve fibres constitute 80-91% of peripheral nerve fibres and control pain perception, 
autonomic and sudomotor function. Although intraepidermal nerve fibre density 
measurement from lower limb skin biopsy is considered the gold standard for the diagnosis 
of small fibre neuropathy [45,46] it is invasive and hence not suitable for routine screening. 
However, a number of POCDs have been developed to assess small fibre dysfunction. 
These include: 
2. NeuroQuick 
Thinly myelinated AG and unmyelinated C-fibres are small calibre nerves that mediate 
thermal sensation and nociceptive stimuli. Quantitative sensory testing of thermal 
discrimination thresholds is a non-invasive test used to examine impaired small nerve fibre 
function. NeuroQuick is a handheld device for quantitative bedside testing of cold thermal 
perception threshold. It allows near patient assessment of small fibre dysfunction avoiding 
the use of time-consuming and expensive quantitative sensory testing equipment in a 
laboratory. To date, one published clinical validation study has been performed in a diabetic 
population which suggests it is a valid and reliable screening tool for the assessment of 
small fibre dysfunction [34]. Use of NeuroQuick was more sensitive in detecting early DPN 
compared to the traditional bedside screening tests such as the tuning fork or elaborate 
thermal testing [34]. However, it is a psychophysical test that relies on the cognition/attention 
of the patient. Furthermore, the coefficients of variation for repeated NeuroQuick 
measurements ranged between 8.5% and 20.4% [34]. Further studies are required to 
demonstrate whether the NeuroQuick is a useful screening tool to detect small fibre 
dysfunction in DPN. 
3. NeuroPad 
This is a 10-minute test which measures sweat production on the plantar surface of the foot. 
It is based on a colour change in a cobalt compound from blue to pink which produces a 
categorical output with a modest diagnostic performance for DPN compared to 
electrophysiological assessments. No training is required to administer Neuropad, nor does 
it require responses from the patient. Therefore, this method of assessment may be more 
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suitable for screening in community settings and those with cognitive or communication 
difficulties who have to respond to other methods of assessment. A number of clinical 
validation studies [47-49] have been conducted which demonstrates low sensitivity for large 
fibre neuropathy (50-64%) but much higher sensitivity for small fibre neuropathy (80%) [50]. 
Neuropad has also shown good reproducibility with intra- and inter-observer coefficient of 
variation between 4.1% and 5.1% [51]. The main utility of the Neuropad as a screening tool 
is the exclusion of DPN [52]. 
4. Corneal Confocal Microscopy (CCM) 
Another technique that has attracted significant interest, with a large number of publications 
over the past 15 years, is CCM. This is a non-invasive ophthalmic application that measures 
various structural parameters (e.g. branch density and length) of small corneal nerve fibres 
[53,54]. There have been a number of clinical validation studies including one 3.5-year 
prospective study in T1DM which demonstrated relatively modest to high sensitivity (82%) 
and specificity (69%) of CCM for the incipient DPN [55]. It has good reproducibility for 
corneal nerve fibre length measurements with intra- and inter-observer intraclass correlation 
coefficients of 0.66-0.95 and 0.54-0.93 respectively [56,57]. The reproducibility improves 
with the automated algorithm (intraclass correlation coefficient 1.0) [58]. Currently, CCM is 
used in specialist centres, but would suit widespread application given its easy application 
for patient follow-up. However, large, multicentre, prospective studies are now required to 
confirm that corneal nerve changes unequivocally reflect the complex pathological 
processes in the peripheral nerve. Moreover, the establishment of a normative database and 
technical improvements in automated fibre measurements and wider-area image analysis 
may be useful to increase diagnostic performance. 
5. Sudoscan 
Sudomotor function has been proposed as a surrogate marker for the small fibre 
involvement in DPN [41,42,59]. Sudoscan, provides a quantitative measurement of 
sudomotor function within 3-minutes. Its measurement is based on an electrochemical 
reaction between electrodes and chloride ions, after stimulation of sweat glands by a low-
voltage current (<4volts) [60]. A measurement of electrochemical skin conductance (ESC) 
for the hands and feet, that are rich in sweat glands, is generated from the derivative current 
associated with the applied voltage [60]. Sensitivity and specificity of foot ESC for classifying 
DPN were 87.5% and 76.2%, respectively [42]. The area under the ROC curve (AUC) was 
0.85 [42]. The reproducibility was also tested in T2DM patients in feet and hands were ICC 
0.95 (0.89±0.98) and 0.88 (0.74±0.96) respectively [61]. 
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In summary, the sensitivity of POCDs are acceptable and a combination of devices 
assessing both small and large fibre function should be used for detecting DPN (Table 1). 
However, there is high heterogeneity and patient selection bias in most of the studies. 
Further studies are needed to evaluate the performance of each POCDs based on Wilson 
criteria for screening of undiagnosed DPN at the population level [62]. Prospective studies of 
hard endpoints (e.g. foot ulcerations and lower limb amputations) are also necessary to 
ensure that the benefits of screening are important for patients. The cost-effectiveness of 
implementing screening using these devices also needs to be carefully appraised. POCDs 
provide rapid, non-invasive tests that could be used as an objective screening test for DPN 
in busy diabetic clinics, ensuring adherence to current recommendation of annual 
assessment for all diabetic patients that remains unfulfilled.  
RATIONALE FOR AN EARLY DETECTION AND MULTIFACTORIAL INTERVENTION 
Early detection of DPN can only be advocated if there is robust evidence that early treatment 
or intervention results in better outcomes than at a later stage. Diabetic peripheral 
neuropathy is a culmination of a complex interaction of several aetiologically linked 
pathophysiological processes ±many not fully understood. Although hyperglycaemia and 
duration of diabetes play an important role in DPN, other risk factors have also been 
identified [63,64]. The EuroDiab Prospective Complications study demonstrated that the 
incidence of DPN is associated with other potentially modifiable cardiovascular risk factors, 
including a raised triglyceride level, hypertension, obesity and smoking (Figure 2), [65]. 
Here we discuss potentially modifiable risk factors that could be addressed early to manage 
DPN effectively: 
1) Hyperglycaemia 
Chronic hyperglycaemia plays a key role in the pathogenesis of DPN [66,67]. Through 
several disturbances in the metabolic pathways, hyperglycaemia leads to abnormalities in 
nerve polyol, hexosamine and protein kinase C pathways [68]. This triggers the release of 
proinflammatory cytokines [poly ADP-ribose polymerase (PARP)], the accumulation of 
advanced glycation end products (AGEs) and generation of reactive oxygen species [68] 
[60new]. Simultaneously, microangiopathic changes of the vasa nervorum result in 
neuroischaemia [69]. This is further exacerbated by impaired endothelial nitric-oxide 
mediated vasodilatory mechanisms (nitrosative stress) [70]. Separately and in concert, these 
glucotoxic metabolic and ischaemic changes lead to DPN by producing nervous system 
oxidative stress and apoptosis of both neurons and supporting glia.  
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In the Diabetes Control and Complications Trial (DCCT) intensive insulin treatment in T1DM 
reduced the risk of DPN (78% relative risk reduction) [71,72].  In the Epidemiology of 
Diabetic Complications (EDIC) study, at the 14 years after DCCT closeout, although DPN 
progressed substantially in both treatment groups, its prevalence and incidence remained 
significantly lower in the former intensively treated group [73]. A recent Cochrane review, 
however, indicated that the evidence of the benefit of intensive glucose control in T1DM is 
mainly from studies in younger patients at early stages of the disease and that the effects of 
tight blood glucose control seem to become weaker once complications are established [74]. 
On the other hand, in T2DM improving glycaemic control alone does not have the same 
impact on reducing the incidence of DPN (5-9% relative risk reduction) [74]. Even when trials 
demonstrate tighter glucose control might have a beneficial impact in preventing progression 
of DPN in T2DM, e.g. the ACCORD study [75], confusion arises when it is reported that a 
self-reported history of DPN at baseline was associated with a higher risk of mortality with 
intensive glycaemic treatment [76]. However, in this study, neither MNSI-documented DPN 
nor history of amputation was associated with a differential effect on mortality between the 
two treatment arms. This discrepancy suggests the two methods of detecting DPN may 
identify different populations and merits further investigation. Similar discordance among 
various indices of neuropathy in their strength for predicting outcome was also apparent in 
the DIAD study [77]. Several other long-term studies of multi-factorial cardiovascular risk 
intervention in T2DM [78-81] and pre-diabetes [82] have failed to slow the progression or 
reduce the incidence of DPN. It must be emphasised that DPN was not a primary outcome 
in these trials and its inclusion appears to be an afterthought, as inconsistent and insensitive 
measures to detect and monitor DPN were employed.  
In contrast, when appropriate DPN clinical endpoints are used the outcomes appear more 
promising. The first randomised controlled trial that demonstrated the benefit of intensive 
management on the incidence of DPN in T2DM was the Kumamoto trial [83]. This study 
showed significant improvement in  nerve conduction parameters in the intensively treated 
group demonstrating the importance of choosing the most appropriate surrogate marker of 
DPN. Nearly 50 years ago, a smaller study also utilizing nerve conduction studies 
demonstrated that DPN is reversible in newly diagnosed T2DM patients with appropriate 
treatment [84]. Moreover, in T2DM the choice agents used to achieve targets may also be 
as important as the glucose targets themselves. The BARI 2D trial demonstrated that the 
cumulative incidence of DPN was significantly lower when insulin-sensitizing agents 
(metformin, thiazolidinediones) were used compared to an insulin-providing (sulphonylureas, 
insulin) strategy [85]. 
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2) Dyslipidaemia  
Observational and cross-sectional studies have demonstrated, to varying degrees, an 
association between hyperlipidaemia and DPN [86]. The strongest evidence, however, is for 
the association of elevated levels of triglycerides and DPN [87]. In a study of patients with 
T2DM there was a graded relationship between triglyceride levels and the risk of lower-limb 
amputations [87]. Likewise, another study demonstrated that hypertriglyceridaemia was an 
independent risk factor for loss of sural (myelinated) nerve fibre density and lower limb 
amputations [88]. In addition to hypertriglyceridemia, low-level of HDL cholesterol has been 
reported as an independent risk factor for DPN [86]. However, clinical studies investigating 
the effects of statins on the development of DPN are far from conclusive. This is partly 
because several large statin studies that included patients with diabetes did not report data 
on the development of microvascular disease [89-91] let alone DPN. The Freemantle 
Diabetes Study, an observational study with cross-sectional and longitudinal analysis, 
suggested that statin or fibrate therapy may be associated with a reduced risk of DPN in 
people with T2DM [92]. Two subsequent, relatively small, randomised clinical studies have 
reported improvements in nerve conduction parameters of DPN following 6 to 12 weeks of 
statin treatment [93,94]. The Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study has since, demonstrated that fibrates are beneficial in preventing 
microvascular complications including DPN [95].  
3) Hypertension  
An association between hypertension and DPN has been demonstrated in several 
observational studies in both T2DM [96,97] and T1DM [98]. There is some preliminary 
evidence from relatively small randomised control trials with improvements in DPN based on 
clinical and nerve conduction parameters following antihypertensive treatment with 
angiotensin converting enzyme (ACE) inhibitors [99] and calcium channel blockers [100].  
4) Lifestyle 
Several studies have revealed an association between obesity and DPN even in the 
presence of normoglycaemia [101-104]. Not surprisingly, DPN prevalence increases in 
obese patients with prediabetes and diabetes [105]. Subsequent studies appear to 
demonstrate that adopting a healthy lifestyle incorporating a balanced diet, regular aerobic 
and weight-resistance physical activities may reverse the process, particularly if they are 
undertaken at an early stage of DPN [106-108]. A randomised control study of a 2.5-hour, 
weekly supervised treadmill exercise and dietary intervention programme aimed at 
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normalising body mass index or losing 7% baseline body weight in T2DM demonstrated 
significant improvement in markers (intraepithelial nerve fibre density and regenerative 
capacity) of DPN [109]. However, once DPN is established, restoration of normal weight did 
not show significant improvement [109]. A variety of different dietary interventions have been 
examined including a low fat, low calorie diet in the DPP study [110] and a Mediterranean 
diet [111] but presently there is no consensus on a specific regime. Once again, these 
studies suggest that if the disease is identified early and the appropriate surrogate marker is 
used, DPN can be reversed by lifestyle intervention.  
5) Multiple risk factor lowering interventions 
Based on the studies above, there is some evidence to suggest targeting lifestyle and 
individual risk factors can improve DPN. Disappointingly, however, several large intervention 
studies targeting multiple risk factors (UKPDS [112], STENO-2 [113], ADDITION [114]) failed 
to show a reduction in DPN despite clear benefits in renal and retinal complications. The 
best possible explanation is that the methods used to diagnose/quantify DPN lacked the 
necessary sensitivity or reliability to diagnose/quantity DPN let alone examine differences 
between study groups. The heterogeneity in effect size estimates for DPN in these studies 
supports this view. Nevertheless, the STENO-2 study did show that 4 years of intensive 
multifactorial treatment slowed the progression of autonomic neuropathy (OR, 0.32; 0.12-
0.78) [113]. More recently, publication of the 21-year follow-up showed a reduction in the 
progression to autonomic neuropathy (HR, 0.59; 95% CI, 0.40-0.89) in the intensive 
treatment arm [115]. This data suggests a long-term benefit of earlier multifactorial 
intervention i.e. a legacy effect. Further research is needed to re-examine the impact of 
multifactorial interventions upon DPN using more reliable, reproducible and sensitive 
measures of DPN. 
In summary, although the risk factors for DPN are well recognised, to-date only small-scale 
intervention studies targeting these risk factors have been conducted which have used DPN 
measures WKDW DUH µILW-for-SXUSRVH¶. Nevertheless, most of the current evidence points to 
multiple risk factor intervention as the best way to prevent the development and progression 
of DPN. Unfortunately, despite several clinical trials [116], there has been relatively little 
progress in the development of disease-modifying treatments [117-119] despite some 
advances in the management of symptoms in painful DPN [120-122]. Hence, early 
identifications of subjects with incipient/sub-clinical neuropathy using validated, yet novel 
non-invasive POCDs will allow larger studies to determine if targeted intensified 
cardiometabolic risk factor control can prevent clinical DPN or halt disease progression.  
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FUTURE PERSPECTIVES 
Ultimately, the prevention of DPN will have the greatest impact on reducing amputations 
dramatically as 90% of patients attending the diabetic foot clinic and virtually all diabetes 
amputees have DPN [11]. Clearly, in those with established DPN careful foot ulcer risk 
assessment (including peripheral vascular status, deformity etc.) and appropriate 
management (education, footwear, podiatry) and risk factor management is warranted.  
Currently, a robust system of an annual foot screening, yet alone multifactorial risk factor 
interventions, for all diabetic patients, as advocated by the American Diabetes Association 
and Diabetes UK has not been implemented systematically. This was confirmed by the UK 
National Diabetes Audit (2016) [123] and the US National Health and Nutrition Examination 
Surveys (NHANES) [124]. These showed that the attainment of recommended vascular risk 
management targets was alarmingly low between 19-40%. More worryingly, only 30% adults 
aged 50 years or less achieved these targets. The National Diabetes Foot Care Audit (2014-
17) showed a high prevalence of diabetic foot ulcers where 30% of patients self-presented 
despite an 85% attendance of annual foot surveillance screening. In addition, foot 
surveillance screening did not identify a third of individuals who subsequently developed 
diabetic foot ulcers [125]. This suggests that 1) the current process of care is inadequate 
(involving multiple visits to different members of the clinical team who do not have specialist 
training to assess the level of risk and provide advice/education and signpost/refer patients 
to receive the appropriate interventions/treatment) [126] and 2) the methods used to screen 
for DPN are insensitive and/or lack reliability to accurately measure risk of developing foot 
ulceration.   
To improve clinical outcomes in DPN as in retinopathy and nephropathy, there is an urgent 
need to: 1) diagnose DPN early before overt clinical signs are apparent and 2) assess 
disease progression accurately in order to effectively reduce morbidity and 3) reliably inform 
patients of their underlying risk of foot ulceration. In addition, screening tests should be safe, 
quick and sufficiently simple to provide objective measures in a busy clinical context. Current 
evidence suggests that some of the recently developed POCDs fulfil these criteria. Once 
DPN has reached at a stage detectable by conventional bed-side tools, it might be too 
advanced for any intervention to reverse/halt the process. A meta-analysis of almost all the 
major trials on T2DM showed that when DPN is established, no intervention is effective in 
reversing its progression (Figure 3).  However, there is an increasing body of emerging 
evidence which suggests that multifactorial risk reduction strategies, including structured 
exercise and education on lifestyles, a healthy diet, smoking cessation and obesity 
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management may be effective in preventing the development and progression of DPN, 
particularly at the stage of pre-diabetes and early diabetes [106,107]. 
In the UK, since the roll-out of population-based digital retinal screening programme, 
diabetes is no longer the leading cause of blindness in working age adults [127]. This 
successful screening programme has been well received with an 81% uptake. Likewise, 
following the implementation of a standardised protocol for early detection and management 
for diabetic nephropathy, there has been a significant improvement in the renal outcomes 
[128,129] 6XFK D UREXVW SURJUDP RI VFUHHQLQJGRHVQ¶W H[LVW IRU DPN or the diabetic foot. 
The scale of morbidity and mortality attributed to DPN is not in question. Furthermore, the 
longitudinal examination of cohorts has established the overall course of the condition [130]. 
Undiagnosed DPN is common [131] and by the time symptoms and/or clinical signs develop 
DPN is already well-established and associated with future risk. Up to 30% of patient with 
diabetic foot ulcers self-present despite an 85% attendance of annual foot surveillance 
programme [125]. $ µ2QH-6WRSVHUYLFH¶ is needed to screen for complications in one visit. 
Foot screening could be performed by a specialist podiatrist to assess the level of foot ulcer 
risk and manage patients appropriately, in order to prevent foot ulceration and amputation. 
In addition, DPN screening can be performed using POCDs in patients with normal physical 
examination (e.g. 10g monofilament, 128hz tuning fork, Ipswich touch test, Vibratip) to 
identify the early sub-clinical disease. This intervention was recently piloted in retinal 
screening clinics in a hospital and community setting [132]. A trained podiatrist performed 
detailed assessments of foot ulcer risk and used combined small and large nerve fibre 
assessments (NC-stat DPN-check and Sudoscan) for the diagnosis of subclinical DPN. This 
pilot study also examined WKHIHDVLELOLW\DQGDFFHSWDELOLW\RID³RQH-VWRSFOLQLF´IRUcombined 
screening for all microvascular complications. Combined eye, renal, DPN and foot ulcer risk 
screening was found to have a high uptake, reduced clinic visits, led to an early diagnosis of 
DPN (93.2% sensitivity for the diagnosis of DPN, Figure 4), unmasked new painful DPN, and 
appeared to be an effective model for the early diagnosis of DPN and management of foot 
complications.  
CONCLUSION 
Lower limb amputations are on the rise globally in contrast to other complications of 
diabetes. There is emerging evidence that DPN in T2DM starts early and can even be 
present in pre-diabetes principally driven by vascular risk factors. There is some evidence to 
suggest risk factor management strategies can improve DPN. However, lack of a robust, 
annual foot/DPN screening program utilising sensitive measures to detect neuropathy is 
resulting in the late diagnosis of DPN and the development of foot complications. There is 
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thus a good rationale for implementing a robust annual diabetes microvascular screening 
program, preferably in a ³RQH-VWRS´ service. Early detection of microvascular complications 
including subclinical DPN will allow the implementation of a multi-factorial risk reduction 
strategy when interventions are likely to prevent disease progression. The information that is 
provided about the tests and its outcomes could be tailored so that it is of value and readily 
XQGHUVWRRGE\WKHLQGLYLGXDOEHLQJVFUHHQHGWRPDNHµLQIRUPHGGHFLVLRQV¶. This will lead to 
an integrated partnership model, empowering and enabling patients to self-manage their risk 
factors with positive lifestyle choices, supplemented by an individually-tailored, target-driven 
intervention with carefully selected pharmacotherapy, orthotic devices and podiatry follow-
up. This is the best hope of preventing the rising tide of lower limb amputations in people 
with diabetes.   
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Figures 
Figure 1: Relative 5-year survival after diabetic foot ulcer and the most common cancers. 
Adapted from [3]. 
 
 
 
 
 
 
 
Figure 2: Odds ratios for associations between key risk factors and the incidence of diabetic 
neuropathy with the use of two logistic regression models. Adapted from [51]. 
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Figure 3: Forest plot showing no significant effect of intensive treatment on diabetic 
peripheral neuropathy event or amputation. 
 
 
 
Figure 4: ROC curve for the identification of diabetic distal symmetrical polyneuropathy 
(DPN) using point of care devices: 10g monofilament (MF), DPN-Check [sural sensory nerve 
amplitude (SNAP, PV) and conduction velocity (SNCV, m/s)] and SUDOSCAN feet electrical 
skin conductance (ESC, PS). Symbols ¸, ۆ and * represent cut off points for DPN-Check 
SNCV, SNAP and SUDOSCAN feet ESC respectively. Adapted from [122]. 
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Table 1: Clinical utility of devices used for the diagnosis of DPN (adapted from Papanas et 
al) [33]. *Intraclass correlation coefficient using an automated algorithm; N/A not available. 
Devices Function Fibres 
Assessed 
Validated 
against 
Sensitivity (%) 
/Specificity (%) 
Intra/Inter 
Observer 
ICC 
Early 
Diagnosis 
DPN Check 
[37,124,133] 
Sural 
Sensory 
Nerve 
function 
Large 
ADAb 
fibres
Nerve 
conduction 
studies, 
Standardised 
clinical 
examination, 
Laser Doppler 
LDI flare 
84.3-90.5/68.3-
86.1 
0.94-
0.97/0.79-
0.83 
Yes 
NeuroQuick 
[34] 
Thermal 
Sensory 
Perception 
Small 
AG/C 
fibres 
Nerve 
conduction 
studies, 
Standardised 
clinical 
examination, 
Vibration 
perception 
threshold, 
 
N/A 0.75-
0.95/N/A 
Yes 
NeuroPad 
[51,52] 
Sudomotor 
Function 
Small C 
fibres 
Nerve 
conduction 
studies, 
Standardised 
clinical 
examination, 
Vibration 
perception 
threshold, Skin 
biopsy IENFD 
65.1-100/32-78.5 4.1/5.1 Yes 
CCM [55-
58,134] 
Corneal 
Nerve Fibre 
Morphometry 
Small C 
fibres 
Nerve 
conduction 
studies, 
Standardised 
clinical 
examination, 
Vibration 
perception 
threshold, Skin 
biopsy IENFD 
82/69 0.66-
0.95/0.54-
0.93 
1.0* 
Yes 
Sudoscan 
[41,61] 
Sudomotor 
Function 
Small C 
fibres 
Nerve 
conduction 
studies, 
Standardised 
clinical 
examination, 
Thermal 
Perception 
Threshold 
87.5/76.2 0.88/0.95 Yes 
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